The Expression And Significance Of Matrix Metalloproteinases And Their Tissue Inhibitors In Cardiac Myxoma

Cardiac Myxoma is common in patients with Cardiac Tumors(CTs).It usually occurs between the ages of 30 and 60 years and is rare in children.Myxoma of the heart usually occurs in the left atrium,with a small number of myxomas occurring in the right atrium and other locations.Most cardiac myxomas are sporadic,however,one of the clinical manifestations of some Carney complex(CNC)patients is also cardiac myxoma.Matrix Metalloproteinases(MMPs)are a family of proteolytic enzymes that can specifically degrade the Extracelluar Matrix(ECM)and participate in the reconstruction of the Extracellular Matrix.Tissue Inhibitor of Metalloproteinase(TIMPs)are endogenous specific Inhibitor of MMPs,participate in the regulation of MMPs.The imbalance of MMPs expression and regulation is associated with a variety of diseases,such as lung diseases,cardiovascular diseases,tumors,etc.Therefore,there is a lot of research on the relationship between MMPs and various diseases.This study was to investigate the expression differences of MMPs/TIMPs in cardiac myxoma tissues in patients with cardiac myxoma under different clinical cardiac function grades and embolization manifestations,so as to further understand the molecular mechanisms that may be related to the formation of cardiac myxoma.Objective:1.To compare the differences of main indicators of echocardiography in cardiac myxoma patients with different clinical cardiac function grades and embolization manifestations.2.To study the effects of different clinical cardiac function grades and embolization manifestations on the expression levels of MMPs and TIMPs in cardiac myxoma tissues.Methods:1.Experiment group: The experiment group was composed of 16 patients whowere diagnosed with cardiac myxoma and underwent cardiac tumor resection in the second affiliated hospital of nanchang university from April 2014 to May2019.According to the NYHA function classification standards,patients were divided into NYHA Class ? or ? group(A)and NYHA Class III or IV group(B).According to the presence or absence of embolization,the patients were divided into the embolization group(I)and the non-embolization group(II).2.Detection contents: Clinical data of 16 patients were collected,and cardiac ultrasound was performed on all patients before surgery,and left ventricular end-diastolic diameter(LVDd),left ventricular ejection fraction(LVEF),left atrial diameter(LAd),and short axis shortening rate(LVFS)were recorded.The expression levels of MMP-2,MMP-9 and TIMP in myxoma tissues of 16 cases were detected by Semi-quantitative reverse transcription-polymerase chain reaction(RT-PCR),and then the results were compared according to the grouping.Results:1.Compared with the NYHA Class ? or ? group(A)and the NYHA Class III or IV group(B),the age of patients with group(A)was less than that of patients with group(B),and there was no statistical difference among the other monitoring indexes of echocardiography.There was no significant difference in echocardiography indexes between the embolization group(I)and the non-embolization group(II).2.Comparison of mRNA expression levels of MMP-2,MM-9 and TIMP-1 in the group A and the group B showed no statistically significant differences.Comparison of mRNA expression levels of MMP-2,MMP-9 and TIMP-1 in the group I and the group II also showed no statistically significant differences.Conclusion:1.Patients with cardiac myxoma have a wide range of symptoms and are difficult to identify.Echocardiography is the primary secondary examination.Once cardiac myxoma is found,surgical treatment should be performed promptly.2.There was no significant change in the main echocardiographic indicators of patients with myxoma of the heart under different clinical cardiac function grading and with or without embolization.3.Different clinical cardiac function grades and embolization manifestations had no significant effect on the expression levels of MMPs and TIMPs in cardiac myxoma tissues.